

Brussels, 6.6.2018 C(2018) 3434 final

ANNEX

ANNEX

to the

COMMISSION IMPLEMENTING DECISION (EU) .../...

on the establishment of a work programme for the assessment of applications for the renewal of approvals of active substances expiring in 2022, 2023 and 2024 in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council

EN EN

ANNEX

- (1) The work programme concerns active substances approved under Regulation (EC) No 1107/2009 which are listed in Part C of the Annex to Implementing Regulation (EU) No 686/2012.
- (2) The priorities for the assessment of applications for the renewal of approvals of the active substances and grouping together similar active substances, as provided for in Article 18 of Regulation (EC) No 1107/2009, are as follows:
 - (a) The assessment of applications for the renewal of approvals of active substances for which, given their properties, it is expected that they may fail to satisfy the approval criteria set out in points 3.6.2 to 3.6.5 and point 3.7 of Annex II to Regulation (EC) No 1107/2009, shall be prioritised. Accordingly, such assessments shall be carried out without delay or with as little delay as possible.
 - (b) The assessment of applications for the renewal of approvals of active substances listed in Part E of the Annex to Regulation (EC) No 540/2011 as candidates for substitution which, given their properties, are approved for no more than seven years, shall be prioritised. Also the assessment of applications for the renewal of approvals of active substances listed in the Annex to Implementing Regulation 2015/408 shall be prioritised. Accordingly, such assessments shall be carried out without delay or with as little delay as possible.
 - (c) Taking into account the similarities in their respective properties, where the dates of dossier submission are different, the approval period shall be extended where appropriate and in due time in accordance with Article 17 of Regulation (EC) No 1107/2009 in order to align the timing of their assessment and the peer-review process carried out by the Authority for the following substances:
 - (i) fluxapyroxad, bixafen, sedaxane, penflufen and penthiopyrad;
 - (ii) disodium phosphonates and potassium phosphonates;
 - (iii) eugenol, geraniol and thymol;
 - (iv) Trichoderma atroviride (strain I 1237) and Trichoderma asperellum (strain T34);
 - (v) benzovindiflupyr and isopyrazam.
 - (d) Where the approval of some active substances not covered by points (a) and (b) is likely to expire before a decision has been taken on the renewal of the approval of such substances for reasons beyond the control of the applicant, the approval period of those active substances shall be extended in due time in accordance with Article 17 of Regulation (EC) No 1107/2009.